FDA-approved nasal spray treatment offering new hope for adults living with treatment-resistant depression.
For many people with depression, standard antidepressant medications provide meaningful relief. But for others—those with treatment-resistant depression (TRD)—two or more antidepressants tried at adequate doses and durations still haven’t been enough. If that describes your experience, you’re not alone, and you’re not out of options.
SPRAVATO (esketamine) nasal spray represents a fundamentally different approach to treating depression. Unlike traditional antidepressants that target the serotonin system, SPRAVATO works on the glutamate system—the brain’s most abundant neurotransmitter—which plays a critical role in neural communication, plasticity, and mood regulation.
SPRAVATO is an NMDA receptor antagonist. By modulating glutamate signaling, it promotes the growth of new neural connections—a process called synaptogenesis—that can help restore brain pathways affected by chronic depression. This mechanism is why SPRAVATO can produce noticeable improvement within hours to days, compared to the weeks or months that traditional antidepressants often require.
FDA-approved and clinically proven. SPRAVATO was first approved by the FDA in 2019 for treatment-resistant depression and received expanded approval in January 2025 as the first and only standalone monotherapy for adults with TRD. Over 100,000 patients in the United States have been treated with SPRAVATO, with safety and efficacy data spanning up to 5 years.
SPRAVATO is FDA-approved for:
SPRAVATO is administered in our REMS-certified clinic under direct medical supervision. Here’s what a typical session looks like:
Total appointment time is approximately 2 to 2.5 hours.
In clinical trials, SPRAVATO has demonstrated meaningful outcomes for patients with treatment-resistant depression:
SPRAVATO is a Schedule III controlled substance administered only in certified healthcare settings. The most common side effects include:
These effects typically begin within 5–10 minutes of treatment and resolve within 30–90 minutes during your monitoring period. Our clinical team is with you throughout the entire process to ensure your comfort and safety.
At Sentry Integrative Mental Health, SPRAVATO is part of a comprehensive, whole-person treatment approach—not an isolated intervention. We consider your full clinical picture, including medications, therapy, lifestyle factors, and overall wellness, to ensure SPRAVATO is the right fit and that you’re getting the most from every treatment session.
Our REMS-certified clinic provides a calm, supportive environment where you can feel safe and cared for during each visit. We believe that how you experience treatment matters as much as the treatment itself.